Literature DB >> 8092339

Naltrexone-induced alterations in human ethanol intoxication.

R M Swift1, W Whelihan, O Kuznetsov, G Buongiorno, H Hsuing.   

Abstract

OBJECTIVE: Outpatient clinical trials with an opioid antagonist, naltrexone, found that this agent reduces relapse drinking in abstinent alcoholics. It is unknown which aspects of intoxication may be affected by naltrexone. The authors investigated the effects of naltrexone on several subjective and objective measures of ethanol intoxication.
METHOD: In a double-blind crossover study, 19 nonalcoholic drinkers received a regimen of naltrexone, 50 mg p.o., or placebo on two different occasions, each time followed by a standard, intoxicating dose of ethanol. Subjective and objective measures of intoxication including mood, physical sensations, performance changes, and ethanol pharmacokinetics were determined. As a control for naltrexone effects, 12 additional subjects received naltrexone or placebo followed by a non-intoxicating, "placebo" dose of ethanol.
RESULTS: Naltrexone augmented certain sedative and discriminant effects of ethanol and reduced positive reinforcing effects without affecting psychomotor performance or ethanol pharmacokinetics. Naltrexone had minimal effects in subjects receiving placebo ethanol.
CONCLUSIONS: The data are compatible with the clinical findings and suggest that the reduction in ethanol consumption by alcoholics following naltrexone administration may occur because of greater subjective intoxication, greater aversive effects, or less positive reinforcement from ethanol.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8092339     DOI: 10.1176/ajp.151.10.1463

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  63 in total

1.  Effects of idazoxan on alcohol pharmacokinetics and intoxication: a preliminary human laboratory study.

Authors:  Carolina L Haass-Koffler; Lorenzo Leggio; Dena Davidson; Robert M Swift
Journal:  Alcohol Clin Exp Res       Date:  2015-04       Impact factor: 3.455

2.  Naltrexone and problems in pain management.

Authors:  A P Vickers; A Jolly
Journal:  BMJ       Date:  2006-01-21

Review 3.  Extended-release intramuscular naltrexone.

Authors:  Tracy Swainston Harrison; Greg L Plosker; Susan J Keam
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  N-methyl-D-aspartate receptor antagonism has differential effects on alcohol craving and drinking in heavy drinkers.

Authors:  Suchitra Krishnan-Sarin; Stephanie S O'Malley; Nicholas Franco; Dana A Cavallo; Meghan Morean; Julia Shi; Brian Pittman; John H Krystal
Journal:  Alcohol Clin Exp Res       Date:  2015-02-09       Impact factor: 3.455

Review 5.  The genetics of alcoholism.

Authors:  David Stacey; Toni-Kim Clarke; Gunter Schumann
Journal:  Curr Psychiatry Rep       Date:  2009-10       Impact factor: 5.285

6.  Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study.

Authors:  Ralitza Gueorguieva; Ran Wu; Dennis Donovan; Bruce J Rounsaville; David Couper; John H Krystal; Stephanie S O'Malley
Journal:  Drug Alcohol Depend       Date:  2009-12-06       Impact factor: 4.492

7.  Subjective effects and changes in steroid hormone concentrations in humans following acute consumption of alcohol.

Authors:  Amira Pierucci-Lagha; Jonathan Covault; Richard Feinn; Rahul T Khisti; A Leslie Morrow; Christine E Marx; Lawrence J Shampine; Henry R Kranzler
Journal:  Psychopharmacology (Berl)       Date:  2005-12-10       Impact factor: 4.530

Review 8.  Relapse prevention and maintaining abstinence in older adults with alcohol-use disorders.

Authors:  Christopher Barrick; Gerard J Connors
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

9.  Effects of naltrexone on cortisol levels in heavy drinkers.

Authors:  Lara A Ray; James Mackillop; Lorenzo Leggio; Marilee Morgan; Kent E Hutchison
Journal:  Pharmacol Biochem Behav       Date:  2008-09-13       Impact factor: 3.533

10.  The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys.

Authors:  Zuzana Justinova; Gianluigi Tanda; Patrik Munzar; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.